COMMUNIQUÉS West-GlobeNewswire

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
13/08/2026
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support Clinical [...]
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA [...]
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
13/08/2026
- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - [...]
Collegium Announces $50 Million Accelerated Share Repurchase Program
13/08/2026
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood [...]
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith [...]
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call [...]
Ascendis Pharma Reports Second Quarter 2026 Financial Results
13/08/2026
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ® – Through July 31, more than 220 unique YUVIWEL patient [...]
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
13/08/2026
Q2 2026 Adjusted EBITDA 1 of $0.9M, the Company’s strongest quarterly performance since 2019 2 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 [...]
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
13/08/2026
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, [...]
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08/2026
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of [...]
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
13/08/2026
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the [...]
ProQR Announces Second Quarter 2026 Operating and Financial Results
13/08/2026
First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference [...]
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop [...]
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
13/08/2026
• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes SAN CARLOS, Calif., [...]
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
13/08/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: [...]
Profusa Announces 1-for-4 Reverse Stock Split
13/08/2026
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
13/08/2026
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; [...]
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for [...]
American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
13/08/2026
Second Quarter Revenue Increased 19% to $8.4 Million Driven by Strong Growth from Direct Patient Services Operating Cash Flow Reached $4.4 Million in First Half of 2026 Conference Call Scheduled for Today at 1:00 PM ET [...]

Pages